The largest improvement in DFS was observed in a prespecified subgroup of stage II-IIIA NSCLC with tumour expression of PD-L1 ≥ 50% (HR 0.43, 95% CI 0.27–0.67). Here, CD274 is linked to non-small cell lung carcinoma.